PL438563A1 - Serum selenium concentration as a marker of survival in patients with malignant melanoma in Poland - Google Patents

Serum selenium concentration as a marker of survival in patients with malignant melanoma in Poland

Info

Publication number
PL438563A1
PL438563A1 PL438563A PL43856321A PL438563A1 PL 438563 A1 PL438563 A1 PL 438563A1 PL 438563 A PL438563 A PL 438563A PL 43856321 A PL43856321 A PL 43856321A PL 438563 A1 PL438563 A1 PL 438563A1
Authority
PL
Poland
Prior art keywords
malignant melanoma
patients
poland
survival
marker
Prior art date
Application number
PL438563A
Other languages
Polish (pl)
Other versions
PL245253B1 (en
Inventor
Jan LUBIŃSKI
Karolina Malińska
Emilia Rogoża-Janiszewska
Tadeusz Dębniak
Original Assignee
Read-Gene Spółka Akcyjna
Pomorski Uniwersytet Medyczny W Szczecinie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna, Pomorski Uniwersytet Medyczny W Szczecinie filed Critical Read-Gene Spółka Akcyjna
Priority to PL438563A priority Critical patent/PL245253B1/en
Publication of PL438563A1 publication Critical patent/PL438563A1/en
Publication of PL245253B1 publication Critical patent/PL245253B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określenia ryzyka zgonu u pacjentów ze zdiagnozowanym czerniakiem złośliwym, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia selenu w surowicy osoby badanej, przy czym stężenie wskazuje na blisko 6-krotnie zmniejszone ryzyko zgonu pacjenta w stosunku do podgrupy ze stężeniem selenu w surowicy zwłaszcza poniżej 76 µg/l, w przypadku występowania wartości stężenia selenu w surowicy zwłaszcza powyżej 96 µg/l.The subject of the application is a method of determining the risk of death in patients diagnosed with malignant melanoma, characterized in that it includes a quantitative assessment of selenium concentration in the test person's serum, the concentration indicating a nearly 6-fold lower risk of death in relation to the subgroup with selenium concentration in especially below 76 µg/l, in the presence of serum selenium concentrations, especially above 96 µg/l.

PL438563A 2021-07-22 2021-07-22 Serum selenium concentration as a survival marker in patients with malignant melanoma in Poland PL245253B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL438563A PL245253B1 (en) 2021-07-22 2021-07-22 Serum selenium concentration as a survival marker in patients with malignant melanoma in Poland

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438563A PL245253B1 (en) 2021-07-22 2021-07-22 Serum selenium concentration as a survival marker in patients with malignant melanoma in Poland

Publications (2)

Publication Number Publication Date
PL438563A1 true PL438563A1 (en) 2023-01-23
PL245253B1 PL245253B1 (en) 2024-06-10

Family

ID=84982736

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438563A PL245253B1 (en) 2021-07-22 2021-07-22 Serum selenium concentration as a survival marker in patients with malignant melanoma in Poland

Country Status (1)

Country Link
PL (1) PL245253B1 (en)

Also Published As

Publication number Publication date
PL245253B1 (en) 2024-06-10

Similar Documents

Publication Publication Date Title
Buckley et al. Serum immunoglobulins: I. Levels in normal children and in uncomplicated childhood allergy
Machado Jr et al. Analysis of discordance between the tuberculin skin test and the interferon-gamma release assay
Sharifi et al. Defining a cutoff point for vitamin D deficiency based on insulin resistance in children
ES2194116T3 (en) PROCEDURE TO DETECT ANTIPOLIMERO ANTIBODIES AND DIAGNOSTIC TEST KIT FOR USE AS HELP IN DIAGNOSIS OF SILICONE-RELATED DISEASES.
Parmar et al. Estimation of postmortem interval through albumin in CSF by simple dye binding method
PL438563A1 (en) Serum selenium concentration as a marker of survival in patients with malignant melanoma in Poland
PL437046A1 (en) Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland
Knovich et al. The association between serum copper and anaemia in the adult Second National Health and Nutrition Examination Survey (NHANES II) population
Ramulu et al. Comparison of Home and Away-From-Home Physical Activity Using Accelerometers and Cellular Network–Based Tracking Devices
Kvetny et al. Subclinical hypothyroidism affects mitochondrial function
Counter et al. Comparative analysis of zinc protoporphyrin and blood lead levels in lead-exposed Andean children
Krysiak et al. Sexual function and depressive symptoms in men with overt hyperthyroidism
PL437897A1 (en) Way to determine the risk of cancer in men according to the concentration of cadmium in the blood
PL436999A1 (en) Serum copper concentration as a prognostic marker in patients with prostate cancer in Poland
Kulkarni et al. Study Of Somen Parameters in male partners among infertile couples.
PL437899A1 (en) Way to determine the risk of cancer in men according to the concentration of lead in the blood
PL438042A1 (en) Serum chromium concentration as a prognostic marker in patients with breast cancer
PL438040A1 (en) Serum manganese concentration as a prognostic marker in patients with breast cancer
PL437608A1 (en) Method of determining the risk of cancer in women according to the concentration of cadmium in the blood
PL438655A1 (en) Method of determining the risk of cancer in women depending on concentration of lead in the blood
PL437894A1 (en) Way to determine the risk of cancer in men according to the concentration of zinc in the blood
Paulsson et al. Hemoglobin adducts in the assessment of potential occupational exposure to acrylamides—three case studies
Dhooge et al. Regional Variations in Semen Quality of Community‐Dwelling Young Men From Flanders Are Not Paralleled by Hormonal Indices of Testicular Function
PL439315A1 (en) The method of determining the risk of cancer in women depending on the concentration of selenium in the blood
Takemoto et al. HuC/D expression in small round cell tumors and neuroendocrine tumors: a useful tool for distinguishing neuroblastoma from childhood small round cell tumors